Physician Fee Cuts Also a Possibility

Publication
Article
OncologyONCOLOGY Vol 15 No 10
Volume 15
Issue 10

As if the prospective Medicare cuts in payments for outpatient chemotherapy drugs were not troubling enough, there is another dark Medicare cloud. The American Medical Association (AMA) is predicting that Medicare may also cut physician

As if the prospective Medicare cuts in payments for outpatient chemotherapydrugs were not troubling enough, there is another dark Medicare cloud. TheAmerican Medical Association (AMA) is predicting that Medicare may also cutphysician fees across the board in 2002. A decision on that will not be madeuntil November, when the CMS presents final numbers for the Medicare EconomicIndex (MEI), an inflation adjustment, and the Sustainable Growth Rate (SGR),which describes how much under or over a preset target physicians’ bills toMedicare were in a given year. 

If physicians keep their billing below theincrease in the gross domestic product, then the MEI is increased, leading to ahigher fee "update." In the opposite scenario, the MEI is decreased.Based on preliminary forecasts, the AMA believes that physician fees could becut 2% to 3% in 2002. (That would be after increases of 5.4% and 4.5% in 2000and 2001.) The AMA is trying to get the CMS to make some administrative changesin the way the MEI and SGR are calculated—changes that perhaps would result ina zero change in 2002. But in a letter to medical specialty societies, RobertGilmore, MD, an AMA official, said, "I cannot overemphasize how difficultthis battle could be."

Recent Videos
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.